⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VERA News
Vera Therapeutics, Inc. Class A Common Stock
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
globenewswire.com
VERA
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
globenewswire.com
VERA
Healthcare Analytics Market Size to Worth USD 166.65 Billion by 2030, at a CAGR of 24.6% – MarketsandMarkets™
globenewswire.com
ORCL
VERA
EXLS
CTAS
HCAT
CVS
MCK
IQV
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VERA
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
globenewswire.com
VERA
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape and Forecast - 2036 | Pan-KRAS Pipelines and New Cancer Indications Drive 7MM Growth
globenewswire.com
AMGN
BMY
VERA
AZN
MRK
Form 8-K
sec.gov
VERA
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
globenewswire.com
VERA
Liberty All-Star ® Growth Fund, Inc. August 2026 Monthly Update
businesswire.com
NVDA
GOOGL
HALO
MSFT
AAPL
META
ASMB
MPWR
EAT
AXON
DDOG
MDB
LLY
RJF
YOU
CGNX
MTRN
LRCX
VERA
WSM
COHR
DHI
KLIC
MOD
UTI
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VERA